AR108761A1 - MODIFIED RNA CODIFYING ENDOTELIAL GROWTH FACTOR POLYPEPTIDES A (VEGF-A), FORMULATIONS AND USES RELATED TO THE SAME - Google Patents
MODIFIED RNA CODIFYING ENDOTELIAL GROWTH FACTOR POLYPEPTIDES A (VEGF-A), FORMULATIONS AND USES RELATED TO THE SAMEInfo
- Publication number
- AR108761A1 AR108761A1 ARP170101533A ARP170101533A AR108761A1 AR 108761 A1 AR108761 A1 AR 108761A1 AR P170101533 A ARP170101533 A AR P170101533A AR P170101533 A ARP170101533 A AR P170101533A AR 108761 A1 AR108761 A1 AR 108761A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- modified rna
- vegf
- codifying
- growth factor
- Prior art date
Links
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 title abstract 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003102 growth factor Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La divulgación se refiere a moléculas de ARN modificadas que codifican polipéptidos de VEGF-A y a formulaciones que comprenden el ARN modificado. Los aspectos de la divulgación se refieren además a preparaciones y a usos de formulaciones que comprenden el ARN modificado para tratar a sujetos que padecen enfermedades sensibles a la terapia con VEGF-A.The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and to formulations comprising the modified RNA. Aspects of the disclosure also relate to preparations and uses of formulations comprising modified RNA to treat subjects suffering from diseases sensitive to VEGF-A therapy.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346979P | 2016-06-07 | 2016-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108761A1 true AR108761A1 (en) | 2018-09-26 |
Family
ID=63667401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101533A AR108761A1 (en) | 2016-06-07 | 2017-06-05 | MODIFIED RNA CODIFYING ENDOTELIAL GROWTH FACTOR POLYPEPTIDES A (VEGF-A), FORMULATIONS AND USES RELATED TO THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR108761A1 (en) |
-
2017
- 2017-06-05 AR ARP170101533A patent/AR108761A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000036A1 (en) | Modified polypeptides and uses thereof (divisional application no. 201900261) | |
| MX2023015185A (en) | PROTEIN DEGRADERS AND USES THEREOF. | |
| CL2018001522A1 (en) | Focalization of peptides to direct adeno-associated viruses (aavs) | |
| GEAP202114720A (en) | Constructs having a sirp-alpha domain or variant thereof | |
| CO2019002609A2 (en) | Recombinant binding proteins and their uses | |
| CY1120862T1 (en) | INDICATORS OF INDEPENDENCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | |
| PE20190563A1 (en) | OPTIMIZED MINI-DISTROPHIN GENES AND EXPRESSION CASSETS AND THEIR USE | |
| MX2021001098A (en) | Single domain antibodies directed against intracellular antigens. | |
| BR112018071585A2 (en) | formulations of an lsd1 inhibitor | |
| BR112019000195A2 (en) | compositions and methods related to therapeutic cellular systems expressing exogenous rna | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| MX2018005315A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER. | |
| UY35964A (en) | HUMAN ANTIBODIES FOR PD? 1 | |
| EA201890725A1 (en) | PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION | |
| CR20230026A (en) | GDF15 FUSION PROTEINS AND USES OF THESE (DIVISIONAL 2018-0532) | |
| BR112016008806A2 (en) | VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS | |
| CO2018002568A2 (en) | Acetamide thienotriazolodiazepines and uses thereof | |
| CY1124667T1 (en) | MODIFIED RNA ENCODING VEGF-A POLYPEPTIDES, PHARMACEUTICAL FORM, AND USES RELATED THEREOF | |
| CR20180200A (en) | CIANO TIENOTRIAZOLPIRAZINAS AND USES OF THE SAME | |
| EP4331590A3 (en) | Nuclear factor erythroid 2-like 2 (nrf2) for use in treatment of age-related macular degeneration | |
| CL2021002168A1 (en) | Tumor associated peptide; nucleic acid; expression vector; recombinant host cell; method for producing the peptide; activated t lymphocytes and their production method; antibody; tcr; use to treat cancer; kit and pharmaceutical composition; method for producing vaccine; and Aptary (divisional application no. 201702407). | |
| CY1119957T1 (en) | TREATMENT OF PATIENTS WITH THE USE OF ANNOUNCED PHARMACEUTICAL PREPARATION | |
| MX2021010041A (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING PROTEIN KINASE AKT INHIBITORS. | |
| MX2025006169A (en) | Mmp13 binding immunoglobulins | |
| EA202191476A1 (en) | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |